Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base

Canaz, Emel; Grabowski, Jacek; Richter, Rolf; Braicu, Elena Ioana; Chekerov, Radoslav; Sehouli, Jalid

doi:10.1016/j.ygyno.2019.06.014

Cited by 18 publications

(25 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, with the optimization and improvement of treatment methods, more and more patients already have site-distant metastases at the time of initial diagnosis, so it is necessary to fully evaluate the prognosis of patients by combining the risk of different site metastases. Our study found that organ metastasis had a signi cant impact on the 5-year overall survival time of patients, especially lung, liver and bone metastases, consistent with previous reports 17,22,23 .…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Development of A Nomogram to Predict Survival Outcome Among Epithelial Ovarian Cancer Patients With Site-Distant Metastases: A Population-Based Study

Wang

Ren

2020

Preprint

View full text Add to dashboard Cite

Objective. The incidence of initial diagnosis with distant metastasis in patients with epithelial ovarian cancer is not rare, for which the available prognostic evaluation criteria is absent. This study aimed to develop a nomogram score to predict long-term prognosis.Methods. This study analyzed patients with epithelial ovarian cancer from the Surveillance, Epidemiology, and End Results (SEER) database between 1975 and 2016. Multivariable logistic and Cox regression were performed to identify survival trajectories. A nomogram score was used to predict long-term survival probability. Results. A total of 131050 patients were included, 18.2%, 7.8% and 66.1% had localized, regional and distant metastases, respectively. Metastases were inversely associated with high probability of 5-year overall survival outcome, localized (OR, 4.62; 95%CI, 4.45-4.80), regional (OR, 2.47; 95%CI, 2.36-2.59) compared with distant metastases. Survival was poorer among regional (HR, 1.72; 95%CI, 1.65-1.79) and distant (HR, 3.39; 95%CI, 3.29-3.49) metastases at diagnosis. For incidence, 0.9%, 6.7%, 5.8% and 0.2% had bone, liver, lung and brain metastases in the all-cause mortality cohort respectively, 1.6%, 9.9%, 8.8% and 0.3% had bone, liver, lung and brain metastases in the cancer-specific mortality cohort respectively. The median survival among the all-cause mortality cohort was 21.0 months, cancer-specific mortality cohort was 15.0 months. Organ-specific metastases were independently associated with survival prognosis.Conclusions. Nomogram score in estimating the long-term prognosis is feasible, for which contribute to directing clinical treatment and prognosis assessment in patient harboring site-distant metastases.

show abstract

Section: Discussionsupporting

confidence: 92%

“…The main treatment is to control the primary disease. The choice of treatment plan needs to fully evaluate the patient's condition 17,18 . The multidisciplinary combined treatment mode can improve the patient's quality of life and survival time to varying degrees.…”

Section: Discussionmentioning

confidence: 99%

Development of A Nomogram to Predict Survival Outcome Among Epithelial Ovarian Cancer Patients With Site-Distant Metastases: A Population-Based Study

Wang

Ren

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…According to European Society for Medical Oncology and National Comprehensive Cancer Network (NCCN) guidelines for ova r ian Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism carcinoma (6,7), the standard initial chemotherapeutic treatment for patients with stage II-IV ovarian carcinoma is based on carboplatin plus paclitaxel regimens. Those who relapse ≥6 months or <6 months after initial chemotherapy are termed as platinum-sensitive patients and platinum-resistant patients, respectively (8). Almost all patients with recurrent disease eventually develop platinum resistance (9).…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism

Yan

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

The aims of the present study were to investigate the clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma (EOC) who have progressed after standard regimens, and to analyze the vascular endothelial growth factor receptor 2 (VEGFR2) rs2071559 polymorphism. A total of 118 patients with advanced EOC who received apatinib treatment were included in the study. Tumor response was evaluated using progression-free survival (PFS) and overall survival (OS) time, and safety data were documented. Additionally, peripheral blood and peripheral blood mononuclear cell (PBMC) specimens from the patients with EOC were collected to perform the genotyping of genetic polymorphism and assess the mRNA expression of VEGFR2, respectively. The objective response rate across the 118 patients with advanced EOC was 38.98%, the disease control rate was 63.56%, the median PFS time was 4.65 months and the median OS time was 15.10 months. Regarding the polymorphism analysis, the prevalence of rs2071559 in VEGFR2 among the 118 patients with advanced EOC was recorded as the TT genotype in 72 cases (61.02%), TC genotype in 41 cases (34.75%) and CC genotype in 5 cases (4.23%), and the minor allele frequency of rs2071559 was 0.22. The distribution of the three genotypes was in accordance with the Hardy-Weinberg equilibrium (P=0.781). TC and CC genotypes were merged in the subsequent analysis. The prognosis analyses suggested that the median PFS time of patients with the TC/CC genotype and the TT genotype was 3.10 and 5.40 months, respectively (P=0.015). Moreover, the median OS time of the two genotypes was 12.60 and 17.50 months, respectively (P=0.009). However, no association was noted between genotype status of the polymorphism and adverse reactions. Additionally, the mRNA expression analysis indicated that the mRNA expression levels of VEGFR2 in PBMC specimens were significantly different between TT and TC/CC genotypes (P<0.001). The present study suggested that the clinical outcomes of patients with advanced EOC, who progressed after standard regimens and received apatinib treatment, might be influenced by the VEGFR2 rs2071559 polymorphism.

show abstract

“…After recurrence, salvage surgery may be considered. Complete cytoreduction to no-gross residual disease has been found an independent prognostic factor for PFS, irrespective of platinum-free interval (PFI) [ 10 ]. In metastatic disease, chemotherapy regimens as for HGCS can be evaluated.…”

Section: Introductionmentioning

confidence: 99%

“…In metastatic disease, chemotherapy regimens as for HGCS can be evaluated. But, due to relatively low responsiveness to chemotherapy, to choose a platinum-based regimen according to PFI may not be as prognostic as it is in HGOC [ 10 ]. Anti-angiogenic therapy with Bevacizumab, reported in retrospective reviews, has shown RR of 40%, alone or in combination with chemotherapy [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Rare ovarian tumours. Other treatments for ovarian cancer

Gil-Martín

Pardo

Barretina-Ginesta

2020

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Aim The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained. Methods Literature review and ongoing trial information have been used to elaborate this guide. Results Each ovarian cancer type must be identified and treated properly from diagnostic to surgery, adjuvant treatment and metastatic disease. Hormonotherapy can be useful as an alternative treatment, especially in low-grade ovarian cancer and endometrioid subtype. Tumour characterisation is appropriated for treatment selection when targeted therapy is indicated. MEK inhibitors, tyrosine-kinase inhibitors, EGFR inhibitors, therapies against integrins, antibody–drug conjugates and other strategies are described. Antiangiogenics, PARP inhibitors and immunotherapy are discussed in other parts of this publication. Conclusion Different ovarian cancer types must receive the appropriated treatment. Alternative therapies may be evaluated beyond the standard therapy, frequently in a clinical trial, and an individualised molecular study may help to find the best treatment.

show abstract

Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base

Cited by 18 publications

References 37 publications

Development of A Nomogram to Predict Survival Outcome Among Epithelial Ovarian Cancer Patients With Site-Distant Metastases: A Population-Based Study

Development of A Nomogram to Predict Survival Outcome Among Epithelial Ovarian Cancer Patients With Site-Distant Metastases: A Population-Based Study

Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the VEGFR2 polymorphism

Rare ovarian tumours. Other treatments for ovarian cancer

Contact Info

Product

Resources

About